Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Class of 2025
Hammarskjold High School
Superior Collegiate and Vocational Institute
Westgate Collegiate & Vocational Institute
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Theralase Technologies Inc
(TSV:
TLT
)
0.2000
-0.0050 (-2.44%)
Streaming Delayed Price
Updated: 3:49 PM EDT, Jul 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Theralase Technologies Inc
< Previous
1
2
3
Next >
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
September 03, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
August 28, 2024
Via
ACCESSWIRE
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
August 21, 2024
Via
ACCESSWIRE
Theralase(R) Release’s 2Q2024 Financial Statements
August 12, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
July 08, 2024
Via
ACCESSWIRE
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
October 23, 2023
Via
ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 16, 2023
Via
ACCESSWIRE
Theralase(R) Files US Patent for Enhanced Immunotherapy
October 05, 2023
Via
ACCESSWIRE
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
June 20, 2024
Via
ACCESSWIRE
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
June 19, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
June 18, 2024
Via
ACCESSWIRE
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
June 14, 2024
Via
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy
June 12, 2024
Via
ACCESSWIRE
Ruvidar(TM) Enhances Efficacy of Cancer Drug
June 10, 2024
Via
ACCESSWIRE
Theralase(R) Successfully Destroys Lung Cancer
June 06, 2024
Via
ACCESSWIRE
Theralase(R) Technology Effective in Virus Inactivation
June 04, 2024
Via
ACCESSWIRE
Theralase(R) Release's 1Q2024 Financial Statements
May 30, 2024
Via
ACCESSWIRE
Theralase(R) Expands Clinical Team
May 02, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
April 24, 2024
Via
ACCESSWIRE
Theralase(R) Granted Canadian Cancer Vaccine Patent
April 05, 2024
Via
ACCESSWIRE
Theralase(R) Release's 4Q2023 Interim Financial Statements
March 27, 2024
Via
ACCESSWIRE
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
March 26, 2024
Via
ACCESSWIRE
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
February 12, 2024
Via
ACCESSWIRE
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
February 08, 2024
Via
ACCESSWIRE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
February 05, 2024
Via
ACCESSWIRE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
January 15, 2024
Via
ACCESSWIRE
Theralase Release’s 3Q2023 Interim Financial Statements
November 29, 2023
Via
ACCESSWIRE
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
November 29, 2023
Via
ACCESSWIRE
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
November 17, 2023
Via
ACCESSWIRE
Theralase(R) Announces Brokered LIFE Financing
October 23, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
